Clinical Trial Detail

NCT ID NCT02688608
Title Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Texas Southwestern Medical Center
Indications

thyroid gland cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.